Ibrutinib is not an effective drug in primografts of TCF3-PBX1

AIM: The Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is effective in patients with multiple myeloma, non-Hodgkin lymphoma and chronic lymphoblastic leukemia. We previously showed that primary cells of children with TCF3-PBX1 positive B-cell precursor acute lymphoblastic leuke...

Descripción completa

Detalles Bibliográficos
Autores principales: van de Ven, Cesca, Boeree, Aurélie, Stalpers, Femke, Zwaan, C. Michel, Den Boer, Monique L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306596/
https://www.ncbi.nlm.nih.gov/pubmed/32563910
http://dx.doi.org/10.1016/j.tranon.2020.100817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306596/
https://www.ncbi.nlm.nih.gov/pubmed/32563910
http://dx.doi.org/10.1016/j.tranon.2020.100817

Ejemplares similares